IGF1 and neoplasm: These include: age and sex; pre-treatment and early post-treatment TV, GH, and IGF-1 levels; tumor histopathology (Ki-67, somatostatin receptor subtype 2 expression, AIP expression, granularity, β-arrestin expression); imaging characteristics (T2-weighted magnetic resonance imaging signal intensity); genetic factors; and treatment history [12–30].